Telomir Pharmaceuticals Inc (TELO) — 13F Filings Explorer (Q2 2026)

TELO ranks #7253 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

33 institutions disclose a position in TELO, but none treat it as a major bet — even Vanguard Capital Management LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Praetorian Wealth Management, Inc. has trimmed its TELO position for two straight quarters, cutting it by $2.6K while still holding $24.0K.

TELO is down 3.5% today, but institutions show net buying of $1.2M this quarter — a divergence between today's price move and the underlying institutional flow.

TELO reported a net loss of $10.4M in its latest fiscal year.

• Not yet profitable — net loss of $10.4M in the latest fiscal year
• Net income improved year over year, from -$16.5M to -$10.4M
• Operating cash flow was negative, using $3.7M in cash
• Current ratio of 5.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.24x equity — within a conventional range